|June 1, 2014|
|13:57 EDT||CELG||Celgene announced updated OS results from post-hoc analysis of Abraxane study|
Celgene announced updated Overall Survival, OS, results from a post-hoc analysis of its phase III IMPACT, Metastatic Pancreatic Adenocarcinoma Clinical Trial, study of ABRAXANE, paclitaxel protein-bound particles for injectable suspension, in combination with gemcitabine in treatment-na´ve patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology, ASCO, annual meeting in Chicago, Ill. The analysis also showed that the treatment effect on OS for pre-specified subgroups analyzed in the trial remained consistent across patient subgroups. Specifically, patients with Karnofsky Performance Status, KPS, KPS 90-100 had a higher median OS on ABRAXANE plus gemcitabine as compared to gemcitabine alone [median OS 9.7 months vs. 7.9 months. Patients with KPS 70-80 also maintained a benefit [median OS 7.6 months vs. 4.3 months. This updated analysis also evaluated the prognostic effects of CA19-9 and neutrophil-to-lymphocyte ratio, NLR. Both elevated CA19-9 and elevated NLR were associated with poorer survival. Further, treatment with ABRAXANE plus gemcitabine appeared to reduce the effect of CA19-9 as a poor prognostic factor, as similar overall survival was observed regardless of CA19-9 level.
News For CELG From The Last 14 Days
|October 9, 2015|
|07:32 EDT||CELG||Celgene says new Otezla data to be presented at EADV Congress|
Subscribe for More Information
|October 8, 2015|
|07:02 EDT||CELG||Concert Pharmaceuticals achieves $8M milestone from Celgene |
Subscribe for More Information
|06:32 EDT||CELG||Piper Jaffray explains why drug prices are justifiable|
Piper Jaffray's team of Biopharma analysts, led by Joshua Schimmer, explain this morning in research note to investors why they believe drug prices are justifiable. The "fairly lopsided" drug-pricing discussion "noise" has created attractive entry points for stocks in the sector, the analysts argue. They say that after adjusting for actual inflation, the growth of drug prices "does not seem particularly concerning." The current dialogue on the topic under-emphasizes the need to provide "extremely attractive incentives" for companies to embark on the "highly risky, capital-intensive, long-development cycle drug development path which is needed to bring new cures for important diseases," the analysts contend. Schimmer's top picks are Alexion (ALXN), Celgene (CELG) and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC) and Ignyta (RXDX) in the small-cap sector.
|October 7, 2015|
|07:34 EDT||CELG||Alliance for Regenerative Medicine to hold a meeting|
Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 7-9.
|05:14 EDT||CELG||Stocks with implied volatility movement; TAP CELG|
Stocks with implied volatility movement; Molson Coors (TAP) 51, Celgene (CELG) 42 according to iVolatility.
|October 6, 2015|
|12:06 EDT||CELG||Piper's Schimmer sees opportunity in Biopharma on TPP-related selloff|
Piper Jaffray analyst Joshua Schimmer says Biopharma stocks are selling off with some spinning the eight years of exclusivity for biologics as part of the Trans Pacific Partnership as a negative for the industry. The development is a "step forward," especially since it does not over-rule the 12 years' exclusivity for the drugs in the U.S., Schimmer tells investors in an intraday research note. While the sector asked for 12 years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argues. His top picks remain Alexion (ALXN), Celgene (CELG) and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC) and Ignyta (RXDX) in the small-cap sector. Further, Schimmer writes that more names look "increasingly compelling" amid the selloff.
|October 2, 2015|
|10:51 EDT||CELG||Celgene October calls active|
Celgene October 120 and 121 calls are active on total call volume of 12K contracts (3K puts) on takeover speculation. October weekly call option implied volatility is at 30, October is at 39, November is at 40; compared to its 52-week range of 23 to 55. Active call volume suggests traders taking positions for upside price movement.
|October 1, 2015|
|18:52 EDT||CELG||Celgene could climb 35%, Barron's says|
Celgene shares could climb 35% and shares look like a buy at current prices, Barron's contends in its 'Barron's Take' column. Reference Link
|10:00 EDT||CELG||On The Fly: Analyst Upgrade Summary|
Today's noteworthy upgrades include: AMEC Foster Wheeler (AMFW) upgraded to Neutral from Underperform at Macquarie... Ares Capital (ARCC) upgraded to Outperform from Neutral at Macquarie... Celgene (CELG) upgraded to Overweight from Neutral at JPMorgan... Deutsche Boerse (DBOEY) upgraded to Overweight from Underweight at Barclays... Devon Energy (DVN) upgraded on valuation, catlysts at Bernstein... HeartWare (HTWR) upgraded to Market Perform from Underperform at Northland... IBERIABANK (IBKC) upgraded to Buy from Hold at Sandler O'Neill... JD.com (JD) upgraded to Buy from Hold at Deutsche Bank... Kirby (KEX) upgraded to Neutral from Underperform at Macquarie... Madison Square Garden (MSG) upgraded to Buy from Hold at Jefferies... Microsoft (MSFT) upgraded to Neutral from Underperform at BofA/Merrill... Newell Rubbermaid (NWL) upgraded to Buy from Neutral at B. Riley... Norfolk Southern (NSC) upgraded to Outperform from Peer Perform at Wolfe Research... Pernod Ricard (PDRDY) upgraded to Buy from Neutral at Goldman... RWE AG (RWEOY) upgraded to Sector Perform from Underperform at RBC Capital... SanDisk (SNDK) upgraded to Overweight from Equal Weight at Morgan Stanley... Steven Madden (SHOO) upgraded to Outperform ahead of earnings turn at Telsey Advisory... Trex Company (TREX) upgraded to Strong Buy from Buy at CL King... Universal Health (UHS) upgraded to Overweight from Sector Weight at KeyBanc... Western Digital (WDC) upgraded on transaction, valuation, momentum at Argus... Workday (WDAY) upgraded to Overweight from Equal Weight at Stephens.
|08:33 EDT||CELG||After massive selloff, large biotechs seen leading sector back|
The biotech sector has been among the worst performing groups during the recent stock market volaility, due to broader macroeconomic concerns as well as sector-specific worries about pushback on drug price increases. However, analysts at JPMorgan and Piper Jaffray issued notes defending a leader in the space, Celgene (CELG), and argued that growth in the sector will continue and cannot be ignored by investors for much longer. BUY CELGENE: JPMorgan analyst Cory Kasimov upgraded Celgene to Overweight citing an "increasingly attractive" valuation following the recent pullback in shares. The company is one the "most fundamentally sound biotechs" and shares at current levels are "too compelling to remain on the sidelines," Kasimov tells investors in a research note. The analyst said that not only does Celgene have an "impressive" proprietary pipeline, but he is also confident in the company's ability to identify potentially first-in-class and best-in-class products to partner on or acquire to continue its growth. Kasimov keeps a $152 price target for the stock. HIGH-GROWTH: Piper Jaffray analyst Joshua Schimmer says recent weakness in the biopharma sector has created a "valuation discrepancy" versus non-growth, non-biopharma stocks that he hasn't seen for a number of years. The sector remains in a "prolonged growth cycle" driven by extended product cycles, attractive and improving pipelines and M&A opportunities, Schimmer told investors in a research note titled "Out of The Ashes, A Growth Sector Poised To Fly Higher." The analyst, who expects large-cap biopharma companies to lift the sector out of the recent weakness, listed Celgene, Alexion (ALXN), Amgen (AMGN) and Endo (ENDP) as his preferred growth names. PRICE ACTION: Celgene shares are down more than 8% over the past month, though the stock closed yesterday up $2.79 to $108.13. During September, Alexion declined 9%, Amgen dropped 9%, Endo fell 10% and the iShares NASDAQ Biotechnology Index ETF (IBB) slid more than 11%.
|06:28 EDT||CELG||Piper sees 'highly compelling' entry points in large cap biopharma|
Piper Jaffray analyst Joshua Schimmer says recent weakness in the biopharma sector has created a "valuation discrepancy" versus non-growth peers that he hasn't seen for a number of years. The sector remains in a "prolonged growth cycle" driven by extended product cycles, attractive and improving pipelines and M&A opportunities, Schimmer tells investors in a research note titled "Out of The Ashes, A Growth Sector Poised To Fly Higher." He expects large-cap biopharma companies to lift the sector out of the recent weakness. His preferred growth names include Celgene (CELG), Alexion (ALXN), Amgen (AMGN) and Endo (ENDP).
|05:47 EDT||CELG||Celgene upgraded to Overweight from Neutral at JPMorgan|
JPMorgan analyst Cory Kasimov upgraded Celgene to Overweight citing an "increasingly attractive" valuation following the recent pullback in shares. The company is one the "most fundamentally sound biotechs" and shares at current levels are "too compelling to remain on the sidelines," Kasimov tells investors in a research note. He keeps a $152 price target for the stock. Celgene closed yesterday up $2.79 to $108.13. Shares are down 8% over the past month.
|September 29, 2015|
|11:11 EDT||CELG||Stocks with call strike movement; CELG GILD|
Subscribe for More Information